NCT04986540

A Trial of SHR - 1906 in Healthy Subjects

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single IV Infusion of SHR-1906 in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 72 (actual)
• Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This study is a phase 1 single dose escalation study of SHR-1906 in healthy subjects. The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of SHR-1906 in healthy subjects.

Conditions

• Idiopathic Pulmonary Fibrosis

Interventions

Type	Name	Description
DRUG	SHR-1906；Placebo	Drug: SHR-1906 IV, single dose Drug: Placebo IV, single dose

Timeline

• Start date: 2021-08-10
• Primary completion: 2022-09-07
• Completion: 2022-09-07
• First posted: 2021-08-03
• Last updated: 2023-02-16

Locations

1 site across 1 country: China